[Expression and clinical significance of ADAM19 in endometrial carcinoma].
To investigate the expression of adamalysin19 (ADAM19) in human endometrial carcinoma and to explore its correlation with clinical behavior and pathological characters. Immunohistochemistry was conducted to detect the expression of ADAM19 in the endometrial tissue from 51 patients with endometrial carcinoma and 33 patients with normal endometrium.The results were analyzed with clinical data. Postive expression signals of ADAM19 were detected both in the endome-trial cancer tissue and normal endometrium. The expression level of ADAM19 in endometrial cancer tissue was significantly higher than that in normal endometrium (P<0.001).Those with lower histological grade or non-adenocarcinoma had a higher expression level(P=0.028 , P=0.042). In addition, ADAM19 in thecarcinoma with myometrial invasion had a higher expression trend than that without myometrial invasion (P=0.065). However, from the clinical data we found no correlation with surgical staging and metastasis of lymph nodes(P=0.328, P=0.529). The overexpression of ADAM19 suggests that ADAM19 correlates with the progress and prognosis of endometrial carcinoma, and may be implicated as a marker for the clinical behavior of endometrial carcinoma.